Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aparolitolovureli Plus Chemotherapy for Borderline Resectable Esophageal Cancer
NCT07283991Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2025
- Primary completion
- Aug 2026
01
Overview
Phase 2, open-label, single-arm trial in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Ruijin Hospital. Primary endpoint: R0 resection rate. Planned start Dec 2025; status: not yet recruiting.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07283991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283991.